Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28058205 | 0.85 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL770511 | 0.75 | — | — | |
| SCHEMBL5703252 | 0.73 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL10775300 | 0.72 | CYP1A2 (0.44) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL10774762 | 0.72 | CYP1A2 (0.44) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL329132 | 0.72 | CYP1A2 (0.44) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL13266798 | 0.72 | CYP1A2 (0.44) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL15977058 | 0.72 | — | — | |
| SCHEMBL108269 | 0.72 | — | — | |
| SCHEMBL10774246 | 0.70 | CYP1A2 (0.43) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145089-A1 | PREPARATION OF (POLY)SULFIDE ALKOXYSILANES AND NOVEL INTERMEDIATES THEREFOR | RHODIA OPERATIONS (FR) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145089-A1 | PREPARATION OF (POLY)SULFIDE ALKOXYSILANES AND NOVEL INTERMEDIATES THEREFOR | TST, CTH, CBS | ALDH1A1 1885/4885LMNA 4645/4885MAPT 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.